4D-PRODRUG
A BRIEF EXPLANATION
4D-PRODRUG develops smart, bio-based materials made from elastin-like proteins (ELPs). These biohybrid materials respond specifically to external stimuli such as temperature or pH, allowing them to change their properties and shape. In 4D printing, a three-dimensional structure is first created, which then evolves over time. The goal is to develop novel carrier matrices for pharmaceuticals that enable controlled drug release and can be adapted to the varying requirements of different drug formulations. The project combines biotechnologically produced proteins, chemical functionalization, and an ultra-fast, contactless 4D printing process. The manufacturing processes are comprehensively documented using data to develop reproducible materials and processes and to enable AI-supported analyses in the future.

Schematic representation of the collaborative project: from biotechnological ELP production through chemical functionalization and 4D printing (light-sheet laser writing) to data-driven analysis and application.
Why We Need 4D-PRODRUG
The demand for new functional materials in medicine and pharmacy is growing steadily. Active ingredients that are poorly soluble, unstable, or problematic from a sensory perspective require biocompatible, scalable, and patient-adaptable systems that enable controlled release, taste masking, and reproducible processing. Conventional materials are increasingly reaching their limits in this regard. There is a need for adaptive materials that respond to external stimuli, thereby opening up new possibilities for modern drug formulations.
How is the project progressing?
- Biotechnological Production of ELPs – Elastin-like proteins (ELPs) are produced as bio-based raw materials.
- Functionalizing Biohybrid ELPs – Targeted chemical modification results in biohybrid ELPs (bELPs) with controllable physicochemical properties.
- Developing stimulus-responsive carrier matrices —The materials are designed to respond to temperature or pH and release active ingredients in a controlled manner.
- Using LSLW for 4D Printing – The materials are processed using a contactless, Light-Sheet-Laser-Writing (LSLW)-based high-throughput process. In addition to the spatial structure, this process also makes use of time-dependent material changes.
- Collecting and Processing Data – Process and material data are systematically documented to support reproducibility and lay the groundwork for future AI-driven analyses.
What's new about it?
The innovation lies primarily in the combination of several approaches: biotechnologically produced, biohybrid ELP materials are chemically functionalized and then processed using contactless light-sheet laser writing. The goal is to create a modular material system that combines a bio-based and more sustainable approach to materials, biological compatibility, customizable functions, and the potential for further processing using process engineering. The time-dependent changes in the printed structures define the 4D nature of this approach.
Looking ahead, this technology could open up new avenues for the formulation of sophisticated active ingredients. Furthermore, the concepts developed are expected to be transferable to regenerative medicine and functional biomaterials research. The systematic collection of material, process, and test data simultaneously supports data-driven materials research and can facilitate the development of usable materials data repositories.
Who is participating?
Goethe University Frankfurt
Project coordination, as well as the development and functionalization of ELP biomaterials at the Institute of Pharmaceutical Technology; cell biology compatibility testing at the Institute of Cell Biology and Neuroscience
Frankfurt Institute for Advanced Studies
Modeling of material behavior and AI-based analysis of material and process data
Glatt, LLC
Transition of the 4D printing process to industry-ready methods and scaling up to application readiness